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Naturally Occurring Antibodies That Recognize Linear Epitopes in the
Amino Terminus of the Hepatitis C Virus E2 Protein Confer
Noninterfering, Additive Neutralization
Alexander W. Tarr,a,b Richard A. Urbanowicz,a,b Dhanya Jayaraj,a,b Richard J. P. Brown,a,b Jane A. McKeating,c William L. Irving,a,b
and Jonathan K. Balla,b
School of Molecular Medical Sciencesa and Nottingham Digestive Diseases Centre Biomedical Research Unit,b The University of Nottingham, Queen’s Medical Centre,
Nottingham, United Kingdom, and Institute of Biomedical Research, University of Birmingham, Birmingham, United Kingdomc
Chronic hepatitis C virus (HCV) infection can persist even in the presence of a broadly neutralizing antibody response. Various
mechanisms that underpin viral persistence have been proposed, and one of the most recently proposed mechanisms is the pres-
ence of interfering antibodies that negate neutralizing responses. Specifically, it has been proposed that antibodies targeting
broadly neutralizing epitopes located within a region of E2 encompassing residues 412 to 423 can be inhibited by nonneutraliz-
ing antibodies binding to a less conserved region encompassing residues 434 to 446. To investigate this phenomenon, we charac-
terized the neutralizing and inhibitory effects of human-derived affinity-purified immunoglobulin fractions andmurine mono-
clonal antibodies and show that antibodies to both regions neutralize HCV pseudoparticle (HCVpp) and cell culture-infectious
virus (HCVcc) infection albeit with different breadths and potencies. Epitope mapping revealed the presence of overlapping but
distinct epitopes in both regions, which may explain the observed differences in neutralizing phenotypes. Crucially, we failed to
demonstrate any inhibition between these two groups of antibodies, suggesting that interference by nonneutralizing antibodies,
at least for the region encompassing residues 434 to 446, does not provide a mechanism for HCV persistence in chronically in-
fected individuals.
Hepatitis C virus (HCV) has infected approximately 180 mil-lion people worldwide (2). Following infection, most people
fail to clear the virus, and a chronic infection, often with serious
sequelae, ensues (1, 38). HCV-related end-stage liver disease is the
leading indication for liver transplantation, and reinfection of the
grafted liver occurs rapidly (32). A systematic review of the re-
search literature recently suggested that there is little, if any, ben-
efit gained by the treatment of liver transplant recipients with
standard antiviral regimens (24), and possible adverse effects as-
sociated with newly emerging direct-acting antivirals may limit
their usefulness in this clinical setting. Antibodies are usually well
tolerated, and the successful administration of anti-hepatitis B
virus immunoglobulin (Ig) (HBIG) (50, 59) sets an important
precedent for HCV. The administration of HCV-neutralizing an-
tibodies during the anhepatic phase and following transplantation
could likewise prevent the reinfection of the grafted liver; the re-
duced incidence of HCV in individuals receiving HBIG contain-
ing anti-HCV antibodies (20) supports this notion. However, to
date, the therapeutic administration of serum immunoglobulin or
monoclonal antibodies targeting HCV has been disappointing
(10, 51), indicating that further studies of the polyclonal response
are needed, if we are to harness the opportunity that antibody
therapy offers.
There is also an urgent need for the development of safe and
effective HCV vaccines to prevent infection. Significant progress
has been made toward T-cell-based vaccines (22), but these vac-
cines will not be sufficient to elicit sterilizing immunity. Conse-
quently, the development of an antibody-targeted vaccine is still a
priority. Protective vaccineswill have to overcome significant viral
antigenic diversity. HCV can be classified into seven genetically
distinct genotypes and can be further subdivided into at least 70
subtypes, which differ by approximately 30% and 15% at the nu-
cleotide level (29, 53). Within an infected individual, the virus
exists as a quasispecies composed of genetically related yet distinct
variants, and this variability allows the virus to escape host immu-
nity (52). The envelope glycoproteins E1 and E2 are the natural
targets of the neutralizing antibody response and are two of the
most variable HCV proteins (8). E1 and E2 are N-linked glyco-
sylated trans-membrane proteins with anN-terminal ectodomain
and a C-terminal hydrophobic membrane anchor (reviewed in
reference 25) that mediate interactions with a range of cell surface
molecules that result in entry via endocytosis. HCV entry requires
interactions with a number of cell receptors, which include CD81,
scavenger receptor class B type I (SR-BI), and members of the
claudin and occludin tight-junction family of proteins (3, 5, 6, 16,
48a, 64, 67).
The development of a potent early neutralizing antibody re-
sponse is associated with a spontaneous resolution of acute infec-
tion (12, 48). Antibodies that target both restricted and broadly
neutralizing epitopes have been described. In general, antibodies
with a restricted range target the first hypervariable region of E2,
and quasispecies evolution leads to rapid escape (68). A number of
more broadly neutralizing antibodies that target linear and con-
formational epitopes overlapping discontinuous regions of E2 in-
volved in CD81 binding have been described (28, 31, 34, 44, 47,
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56). One of these regions, encompassing amino acids (aa) 412 to
423 (in reference to the sequence of the H77c molecular clone), is
targeted by the broadly neutralizing monoclonal antibodies
(MAbs) AP33 and 3/11 (56). Antibodies that target this region are
rare in natural infection, suggesting that this region is poorly im-
munogenic (55).
A number of mechanisms have been proposed to explain how
HCV can persist in the presence of neutralizing antibodies. These
proposed mechanisms include genetic escape (61), the occlusion
of neutralizing epitopes through glycan shielding (18, 26) and
lipid associations (23, 54), infection enhancement via serum com-
ponents such as high-density lipoprotein (HDL) and apolipopro-
teins (13, 14, 60), and cell-to-cell transmission (7, 63). An addi-
tional mechanism was recently proposed by Zhang and
colleagues, who reported that a linear region of E2 encompassing
amino acids 434 to 446 (the so-called epitope II) elicits nonneu-
tralizing antibodies in humans and chimpanzees that can inhibit
the neutralizing activity of antibodies targeting aa 412 to 423 (65,
66). However, previous reports suggested that murine monoclo-
nal antibodies, for example, MAbs 2/69a, 7/16b, and 11/20c,
whose epitopes overlap the region encompassing aa 434 to 446,
neutralize autologous H77c pseudoparticle (HCVpp) infection
and CD81 binding (9, 27). If both findings are true, then this
suggests that antibodies that target the region encompassing aa
434 to 446 differ in phenotype according to their epitope specific-
ity or that antibodies that target this region exhibit a dual pheno-
type.
To better understand the interplay between these groups of
antibodies, we isolated human Ig fractions by peptide immunoaf-
finity techniques and characterized the resulting antibodies to-
gether with defined murine MAbs. The neutralizing phenotype,
degree of cross-competition, and epitope specificity were assessed.
Contrary to previous reports, we failed to observe inhibition or
competition between antibodies specific for these two groups.
Our data show that human antibodies that target the region en-
compassing aa 434 to 446 neutralize HCVpp and HCVcc infec-
tion. Importantly, these antibodies augment neutralizationmedi-
ated by antibodies that target the region encompassing aa 412
to 423.
MATERIALS AND METHODS
Peptides and MAbs. Biotinylated peptides were synthesized by using
Synphase PA lanterns (Mimotopes, Melbourne, Australia), using a
C-terminal biocytin residue separated from the epitope sequence by a
Gly-Ser-Gly spacer sequence. Peptide purity was assessed by matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF) spec-
trometry. Peptides were initially dissolved in dimethyl sulfoxide (DMSO)
and then dissolved in phosphate-buffered saline (PBS) to a final concen-
tration of 1 mg/ml in PBS. The peptides corresponded to amino acids 412
to 423 (QLINTNGSWHIN [peptide I]) and amino acids 434 to 446 (NT
GWLAGLFYQHK [peptide II]) of the HCVH77c polyprotein and a con-
trol peptide corresponded to a seroreactive region of the rabies virus gly-
coprotein (VNLHDFRSDEIE) (11). Where appropriate, anti-E2 MAbs
2/69a (21) and AP33 (43) were used as control antibodies.
Patient samples. Patient samples were obtained with ethics commit-
tee approval from the Trent HCV Cohort Study. Sera from 557 HCV
antibody-positive (third-generation enzyme-linked immunosorbent as-
say [ELISA]; Ortho Diagnostics) individuals chronically infected with di-
verse HCV genotypes were inactivated by heating to 56°C for 30 min
before use.
Peptide capture immunoassay.Neutravidin (Pierce) was coated onto
Maxisorp plates (Nunc) at 5 g ml1 in 50 mM carbonate-bicarbonate
buffer (pH 9.8; Sigma). Unbound Neutravidin was removed by washing
with PBS containing 0.05% Tween 20 (PBS-T), and nonspecific binding
sites were blocked by using PBS-T containing 3% bovine serum albumin
(PBS-TB). Peptide solutions (1 g ml1 in PBS-T) were incubated at
room temperature for 1 h. Unbound peptide was removed, and human
sera, diluted 1/50 in PBS-T, were bound to the capture peptide for 2 h at
room temperature. Unbound sera were removed with three washes, and
bound immunoglobulin was detected with an alkaline phosphatase-
conjugated anti-human IgG antibody (Sigma) and diluted 1/2,000 in a
Tris-buffered saline–0.05% Tween 20 solution (TBS-T), followed by
p-nitrophenol phosphate (pNPP) substrate (Sigma). The absorbance at
405 nm was determined by using a BMG Labtech Optima plate reader.
The negative cutoff was calculated as twice the mean of three HCV
antibody-negative human serum control wells. Assays using purified im-
munoglobulin were performed essentially as described above, with de-
fined concentrations of Ig.
Peptide-based immunoaffinity purification. Streptavidin-coated
M280 Dynabeads (Invitrogen) were coated with biotin-labeled peptides,
representing the amino acid sequences of strain H77c encompassing
amino acids 412 to 423 or 434 to 446, according to the manufacturer’s
instructions. Beads were incubated with 400 l of patient sera for 4 h at
room temperature, washed six times, and incubated with antibody elu-
tion buffer (Thermo) for 10 min. Following the removal of the beads,
antibody-containing solution was neutralized with 1 M Tris (pH 8.5). As
a negative control, serum was incubated with streptavidin-coated Dyna-
beads in the absence of peptide. Antibody-containing solutions were ali-
quoted and stored at20°C for further assays.
Epitope mapping by enrichment of random peptide phage display
libraries. Purified Ig fractions were used to selectively enrich a 12-mer
random peptide phage display library (NEB), as described previously
(56). Following three rounds of enrichment, individual phage clones were
isolated, and the peptide insert was determined by using a96 sequenc-
ing primer (NEB). Sequencing products were resolved by using an ABI
3100 capillary sequencer. The deduced peptide insert amino acid se-
quences and the sequence corresponding to amino acids 412 to 423 or 434
to 446 of the H77c strain were aligned by using ClustalX (58). Enzyme
immunoassays (EIAs)were also performed to determine the reactivities of
the Ig fractions and control MAbs to the enriched phage clones. Approx-
FIG 1 Amino acid variability in the region encompassing aa 409 to 450 in
circulating HCV isolates. An amino acid alignment of the region of E2 derived
from diverse genotypes of HCV encompassing residues 409 to 450 was per-
formed by using ClustalX. Peptide sequences used in this study are highlighted
by underlined sequences in strain H77c.
Tarr et al.
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imately 1  1011 phage particles were added to microtiter plate wells
coated with 5 g ml1 of MAb or purified Ig, and bound phages were
detected by an anti-fd antibody (Sigma), followed by an alkaline
phosphatase-conjugated anti-mouse antibody (Sigma) and Sigmafast
pNPP substrate. Absorbance values were determined at 405 nm.
HCVpp and HCVcc neutralization assays.Huh-7 human hepatoma
cells (42) and HEK293T human embryonic kidney cells (ATCC CRL-
1573) were propagated as described previously (9). cDNA sequences en-
coding full-length E1E2 were previously cloned into the pcDNA3.1 V5his
D-TOPO expression vector (Invitrogen) (33). HCVpp were produced
essentially as previously reported (5). Pseudoparticles generated in the
absence of the E1E2 plasmid were used as a negative control. For neutral-
ization assays, sucrose cushion-purified HCVpp were mixed with dilu-
tions of purified Ig or MAb, incubated for 1 h at 37°C, and then added to
Huh-7 cells plated into a 96-well Optilux plate (BD Biosciences) contain-
ing 100 l medium, and the plates were incubated for 4 h before an
additional 100l of mediumwas added. Cultures were incubated at 37°C
for 3 days in the presence of 5% CO2. Following the removal of medium,
cells infected with HCVpp were lysed with 20 l of cell lysis buffer (Pro-
mega), and 50 l of luciferase substrate (Promega) was added. Lumines-
cence was measured by using a BMG Labtech Optima plate reader.
Huh7.5 cells were grown in Dulbecco’s modified Eagle medium
(DMEM) (Invitrogen) supplemented with 10% fetal calf serum and 0.1
mM nonessential amino acids. Plasmids containing JFH-1, H77c/JFH-1,
and JFH-1GND genome cDNAs were used to produce HCVcc as de-
scribed previously (30, 35, 62). Cell supernatants were harvested and fil-
tered through a 0.45-mnitrocellulosemembrane. Following staining for
the presence of NS5A, infectious-virus titers were determined according
to the method of Reed and Muench (49). For neutralization assays, 100
focus-forming units of virus was incubated with serial dilutions of anti-
bodies and added to Huh7.5 cells following 1 h of incubation, and infec-
tion was revealed as described above. Inhibition was determined by com-
parisonwith an uninhibited control. In all experiments, a negative control
was prepared by using the GND replication-defective HCVcc mutant.
PCR amplification of E1E2 coding sequences from patient sera.
E1E2 sequences were amplified following RNA isolation from infected
sera, as previously described (30). Briefly, RNA was extracted by using a
Viral RNA kit (Qiagen), and cDNAwas generated by using Thermoscript
reverse transcriptase (Invitrogen). E1E2 sequences were amplified by us-
ing LongAmp Taq (NEB) and sequenced with an internal sequencing
primer using BigDye sequencing chemistry (Applied Biosystems).
Statistical analysis.Differences betweenmeanswere assessed by using
t tests and one-way analysis of variance (ANOVA) with Bonferroni post-
test correction, as appropriate. All analyses were performed by using
Graphpad Prism, version 5, software.
RESULTS
Individuals with antibodies that target the region of E2 encom-
passing aa 412 to 423 frequently harbor antibodies that recog-
nize the region of E2 encompassing aa 434 to 446. Extending our
previously reported analyses (55), a total of 557 distinct sera ob-
tained from individuals infected with diverse genotypes of HCV
were screened for the presence of antibodies directed to a peptide
representing amino acids 412 to 423 of strain H77c (peptide I).
FIG 2 The serum antibody response to peptide I and peptide II is maintained
over time. Sequential serum samples obtained from patients 1A76 and 3A64
were tested for reactivity to immobilized peptide I (corresponding to the re-
gion of E2 encompassing aa 412 to 423) and peptide II (E2 region encompass-
ing aa 434 to 446) in an enzyme immunoassay. (A) 1A76-Ig reactivity to pep-
tide I () or peptide II (). (B) 3A64-Ig reactivity to peptide I () or peptide
II (Œ). Arrows indicate the samples used as a source of immunoglobulin frac-
tions for subsequent analyses. OD405, optical density at 405 nm.
FIG 3 Affinity-purified immunoglobulins demonstrate dose-dependent and
specific binding to their selecting peptides. Immunoglobulin fractions were
obtained from sera from patients 1A76 and 3A64 by affinity purification using
peptide I (peptide I-Ig) and peptide II (peptide II-Ig), which correspond to E2
regions encompassing aa 412 to 423 and aa 434 to 446, respectively. Affinity-
purified immunoglobulin and monoclonal antibodies AP33 and 2/69a were
tested by an immunoassay for reactivity to immobilized peptide I (A) or pep-
tide II (B). , 1A76 peptide I-Ig; , 3A64 peptide I-Ig;, 1A76 peptide II-Ig;
Œ, 3A64 peptide II-Ig; Œ, MAb AP33;o, MAb 2/69a.
HCV-Neutralizing Antibody Response
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Seventeen (2.3%) sera possessed peptide I-reactive antibodies. To
investigate the presence of antibodies directed to the peptide rep-
resenting amino acid residues 434 to 446 (peptide II), peptide
binding assays were performed with those sera that were reactive
with peptide I. Twelve of the 17 sera (70%) also reacted with pep-
tide II, suggesting that these two epitopes are often coimmuno-
genic despite being recognized by the sera of only a small subset of
patients. We then analyzed a subset of the peptide I-negative sera
for binding to peptide II, which showed that the prevalence of
reactivity to peptide II was 14.6% in this population. Although
relatively low, the prevalence of antibodies to the region encom-
passing aa 434 to 446 was much higher than the prevalence of
antibodies to the region encompassing aa 412 to 423. Despite the
fact that the target peptides were based upon a genotype 1a strain
(H77c), peptide-reactive antibodies were detected in sera from
individuals infected with a range of genotypes. This suggested
some degree of epitope conservation despite the observed se-
quence heterogeneity observed across aa 434 to 446 (Fig. 1). Based
upon the availability of sufficient amounts of stored serum, inde-
pendent sera from patients 1A76 (genotype 1a infection) and
3A64 (genotype 3a infection) were selected to further characterize
the neutralizing potency and specificity of the antibody response
to amino acid regions encompassing residues 412 to 423 and 434
to 446.
To identify an appropriate high-titer serum sample for subse-
quent studies, and to define the longitudinal peptide I and peptide
II binding profiles, sequential sera were tested for their abilities to
bind to immobilized peptide I and peptide II (Fig. 2). While some
differences in the relative binding were observed for each serum
and peptide combination, the antibody response to both peptides
in sera from both patients was maintained over a period of several
years. The earliest available serum sample from patient 3A64 pos-
sessed high levels of peptide II-reactive antibodies butmuch lower
levels of antibody reactivity to peptide I, while the other sera from
the same patient had comparable reactivities to both peptides.
One sample from each patient that exhibited detectable reactivity
to both peptides was chosen for further study.
Affinity-enriched antibodies directed to peptide I and pep-
tide II display specific binding to their respective peptides. Pep-
tides corresponding to each E2 region were immobilized onto
streptavidin-coated magnetic beads and used to affinity purify
antibodies from sera frompatients 1A76 and 3A64. This approach
recovered between 10 g and 40 g of antibody per milliliter of
serum. The resulting antibody fractions, as well asMAb AP33 and
MAb 2/69a, demonstrated a level of dose-dependent binding to
the target peptide that was at least 4-fold higher than that of bind-
ing to the reciprocal peptide (Fig. 3).
Peptide I-Ig and peptide II-Ig do not cross-compete for E2
binding.Having purified peptide I- and peptide II-specific immu-
noglobulin fractions (here termed peptide I-Ig and peptide II-Ig),
the accessibilities of their epitopes on H77c E1E2 were assessed
(Fig. 4). MAb AP33 and MAb 2/69a recognized Galanthus nivalis
agglutinin (GNA) captured E1E2, although the latter MAb bound
with a lower relative affinity. Similarly, affinity-purified Ig frac-
tions also bound H77c E1E2 but with differing affinities. Peptide
I-Ig derived from sera of patient 3A64 (3A64 peptide I-Ig) showed
greater binding to E1E2 than did peptide II-Ig. However, the op-
posite was true for the Ig derived from sera of patient 1A76 (Fig.
FIG 4 Antibodies that target the region of E2 encompassing aa 434 to 446 do not compete with antibodies that target the region of E2 encompassing aa 412 to
423 for E1E2 binding. (A) 1A76 peptide I-Ig (), 3A64 peptide I-Ig (), 1A76 peptide II-Ig (), 3A64 peptide II-Ig (Œ), MAb AP33 (Œ), and MAb 2/69a (o)
were tested for their abilities to bind to GNA-captured E1E2 protein from strain H77c. Data are presented as the differences in optical densities between the
antibody sample and a negative control in the absence of target E1E2 protein. (B to E) To test for cross-competition between antibody groups, the binding of
GNA-captured E1E2 to 3A64 peptide I-Ig (B), 3A64 peptide II-Ig (C), 1A76 peptide I-Ig (D), or 1A76 peptide II-Ig (E) was determined in the presence of
competing MAb AP33 (Œ) or MAb 2/69a (o). Data are presented as the percent binding of an uninhibited control. The mean percentages of antibody binding
obtained for the highest concentrations of test and control antibodies were compared by using a t test. P values of0.01 are indicated by double asterisks.
Tarr et al.
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4A). To assess whether the antibodies that target the region en-
compassing aa 434 to 446 are capable of interfering with the neu-
tralizing potential of antibodies that target E2 residues 412 to 426
(65, 66), we first performed competition assays, where the binding
of peptide I-Ig and peptide II-Ig to E2was detected in the presence
of increasing amounts of eitherMAb AP33 orMAb 2/69a (Fig. 4B
to D). E2 binding by peptide I-Ig fractions obtained from both
patients was inhibited, in a dose-dependent manner, by MAb
AP33 but was unaffected byMAb 2/69a (Fig. 4B andD). Similarly,
the binding of peptide II-Ig was inhibited by MAb 2/69a but was
unaffected by MAb AP33 (Fig. 4C and E). Together, these data
showed that the binding of antibodies to the region of E2 encom-
passing aa 412 to 423 was unaffected by antibodies that target the
region encompassing aa 434 to 446 and vice versa.
Peptide I-Ig and peptide II-Ig neutralizeH77cHCVpp infec-
tivity but differ in their abilities to neutralize JFH-1HCVpp.We
next determined the abilities of the peptide I-Ig and peptide II-Ig
fractions andMAbsAP33and2/69a toneutralizeHCVpp-expressing
strain H77c (genotype 1a) and JFH1 (genotype 2a) E1E2 glycopro-
teins. A dose-dependent neutralization ofH77HCVppwas observed
for all of the Ig fractions and MAbs tested (Fig. 5A). Differences in
neutralization potency were evident, with estimated 50% inhibitory
concentrations (IC50s) ranging from 0.1 to 8 g ml1 for the
different peptide I-Ig and peptide II-Ig fractions andmonoclonal an-
tibodies. MAb AP33 was the most potently neutralizing, while MAb
2/69a was the least neutralizing. When tested with HCVpp supple-
mented with E1E2 of the JFH-1 strain, a much lower neutralization
potency was observed at the concentrations tested (Fig. 5B). A dose-
dependent inhibitionof entrywasachievedbyusing the1A76peptide
I-Ig and the 3A64 peptide II-Ig preparations as well asMAbAP33. In
contrast, 1A76 peptide II-Ig, 3A64 peptide I-Ig, and MAb 2/69a did
not neutralize JFH-1HCVpp.This finding suggests that although the
antibodies isolated from patients recognize the same peptide se-
quence, they recognize different epitopes, resulting in different neu-
tralizing phenotypes.
Peptide I-Ig and peptide II-Ig potently neutralize H77c chi-
mericHCVcc infectivity but differ in their abilities to neutralize
wild-type JFH-1 HCVcc. To assess whether the Ig fractions were
capable of neutralizing the entry of authenticHCVcc virions, neu-
tralization assays were performed by using cell culture-grown
JFH-1 virus and a JFH-1 chimera possessing the structural pro-
teins derived from clone H77c (Fig. 6). H77/JFH-1 was neutral-
ized by peptide I-Ig and peptide II-Ig isolated from patients 1A76
and 3A64 as well as by MAb AP33 and MAb 2/69a. Again, the
neutralization of wild-type JFH-1 HCVcc was more variable (Fig.
6B). Dose-dependent neutralization, which differed in potency,
was observed for 1A76 peptide I-Ig, 3A64 peptide I-Ig, 3A64 pep-
tide II-Ig, andMAbAP33. In contrast, both 1A76peptide II-Ig and
MAb 2/69a failed to neutralize JFH-1HCVcc at the antibody con-
centrations tested.
Antibodies that target regions of E2 encompassing aa 412 to
423 and 434 to 446 show additive neutralization.Having shown
FIG 5 Human and murine antibodies that target regions of E2 encompassing aa 412 to 423 and aa 434 to 446 neutralize HCVpp entry but differ in their
neutralization breadths.Dilutions of 1A76peptide I-Ig (), 3A64peptide I-Ig (), 1A76peptide II-Ig (), 3A64peptide II-Ig (Œ),MAbAP33 (Œ), orMAb2/69a
(o) were used to neutralize the infectivity ofH77cHCVpp (A) or JFH-1HCVpp (B). Two different negative controls were used for the neutralization assays ():
a normal human serum sample mock purified using the magnetic bead process was used as a negative control in the Ig neutralization assays, whereas
HIV-1-specific monoclonal antibody 2F5 was used as a negative control in theMAb neutralization assays. Although neutralization assays were performed at the
same time, for clarity, they are plotted on twopanels corresponding to each peptide Ig and a third panel for themonoclonal antibodies. The samenegative-control
NHS data set is included in both Ig panels. Themean infectivities observed at the highest concentrations of each test antibody and the negative-control antibody
were compared by using a t test. P values are indicated as follows: ns, P 0.05; , P 0.01; , P 0.001; , P 0.0001. Themean luminescences observed
for the uninhibited H77c HCVpp and JFH-1 HCVpp were 3,830 relative light units (RLU) and 3,819 RLU, and those for the no-env controls were 165 RLU and
138 RLU, respectively.
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that antibodies that target the region of E2 encompassing aa 434 to
446 bind E2 independently of antibodies that target the region
encompassing aa 412 to 423 and that both groups have a neutral-
izing phenotype, we assessed whether or not antibodies to these
distinct regions could mediate additive neutralization. To assess
this, increasing doses of peptide II-Ig were mixed with autolo-
gous peptide I-Ig at or near its estimated IC50 and then used to
neutralize H77c HCVpp (Fig. 7A) or JFH-1/H77c HCVcc (Fig.
7B). Dose-dependent additive neutralization was observed for
antibodies derived from both patients 1A76 and 3A64, with
maximal combined neutralization reaching 93%. Combina-
tions of MAbs AP33 and 2/69a resulted in the same additive
neutralization, demonstrating that both human and murine
antibodies share this property.
Analysis of circulating variants in patients harboring anti-
bodies directed to regions encompassing aa 412 to 423 and aa
434 to 446.Todetermine if the presence of antibodies to regions
encompassing aa 412 to 423 and aa 434 to 446 resulted in the
selection of variants, we attempted to recover and sequence the
corresponding E1E2 coding regions; only the serum sample
obtained from patient 3A64 was successfully amplified (Fig.
8A). The region encompassing aa 412 to 423 of the majority
sequence was identical to that of H77c, whereas the regions
corresponding to peptide II harbored W437F, L438I, Y442S,
Q443Y, and H444Y substitutions. All substitutions, except
Y442S, are commonly found in genotype 3a sequences in the
GenBank database (Fig. 1).
Peptidemappingof epitopes recognizedbypeptide I-Ig, pep-
tide II-Ig, and MAb 2/69a reveals the presence of multiple
epitopes. We have previously enriched random peptide display
libraries to map the residues critical for MAb AP33 (56). There-
fore, we adopted the same approach to determine residues in-
volved in the binding of peptide I-Ig, peptide II-Ig, and MAb
2/69a. Following 3 to 4 rounds of biopanning, the binding of in-
dividual phage clones to the target Ig/MAbwas assessed, and their
peptide inserts were determined by DNA sequencing. Six of the
seven phage clones isolated using 3A64 peptide I-Ig were strongly
reactive to the selecting peptide I-Ig. Clone 6 had a lower level
of reactivity, although this level of reactivity was still more than
twice that observed for the negative control normal human
serum (NHS) IgG (Fig. 8A). An alignment of the deduced
amino acid sequences of the peptide inserts identified key res-
idues that appeared to be critical for binding (Fig. 8A). One
peptide sequence was identified in 7 independent clones, and
residues that aligned to those present in the corresponding
H77c sequence were L413, I414, N415, T416, G418, S419,
W420, and I422. Analysis of the all of the peptide sequences
showed that the most frequently observed amino acid residues
aligned to the sequence 416TxGxW420.
A similar analysis using 1A76 peptide I-Ig showed that three
of four clones isolated were well recognized by the target Ig
fraction in the phage binding immunoassay (Fig. 8B). Themost
prevalent phage clone sequence was present in 50% of the
clones selected. This sequence possessed residues that mapped
FIG 6 Human and murine antibodies that target regions of E2 encompassing aa 412 to 423 and aa 434 to 446 neutralize HCVcc infection. Dilutions of 1A76
peptide I-Ig (), 3A64 peptide I-Ig (), 1A76 peptide II-Ig (), 3A64 peptide II-Ig (Œ),MAbAP33 (Œ), orMAb 2/69a (o) were used to neutralize the infectivity
of H77cHCVcc (A) or JFH-1HCVcc (B). As for theHCVpp assays, two different negative controls were used in these assays (): a normal human serum sample
mock purified using the magnetic bead process was used as a negative control in the Ig neutralization assays, whereas HIV-1-specific monoclonal antibody 2F5
was used as a negative control in the MAb neutralization assays. Although neutralization assays were performed at the same time, for clarity, they are plotted on
two panels corresponding to each peptide Ig and a third panel for the monoclonal antibodies. The same negative-control NHS data set is included in both Ig
panels. The mean infectivities observed at the highest concentrations of each test antibody and the negative-control antibody were compared by using a t test. P
values are indicated as follows: ns, P 0.05; , P 0.05; , P 0.01; , P 0.0001.
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to positions L413, N415, andW420. The remaining clones were
typified by the presence of a tryptophan, corresponding to res-
idue W420, and either L413 or I414. The clone that was non-
reactive in the phage immunoassay (clone 18) contained a tryp-
tophan but did not contain any other amino acids that aligned
to the E2 sequence.
Similar analyses of the antibodies that target the E2 region cor-
responding to peptide II were also able to identify key residues
involved in binding. Seven clones enriched by 3A64 peptide II-Ig
were selected and analyzed, and of these clones, two showed
specific reactivity to the selecting antibody in the phage immu-
noassay (Fig. 8A). Sequence analysis of these clones revealed
that the most frequent canonical binding sequence was
GWLxG, corresponding to E2 residues G436, W437, L438, and
G440. All phage-displayed peptides enriched by peptide II-Ig
isolated from sera of patient 1A76 also demonstrated specific
binding in the phage enzyme immunoassay, and analyses of the
peptide sequence revealed that these antibodies recognized an
overlapping yet distinct epitope consisting of G436, W437, and
L441. Finally, the residues involved in recognition by MAb
2/69a were defined (Fig. 8C). Key residues were identified as
G440, Y443, and K446. Together, the peptide mapping data
demonstrate that antibodies directed to each of these peptides
recognize overlapping yet distinct epitopes.
DISCUSSION
Studies of both sera and human monoclonal antibodies have
shown that cross-neutralizing antibodies arise during chronic
HCV infection (4, 19, 28, 31, 34, 37, 39, 41, 44, 45, 57). Several
mechanisms have been proposed to explain how HCV persists.
One mechanism proposed recently was the induction of nonneu-
tralizing antibodies that target epitopes within the E2 region en-
compassing amino acid residues 434 to 446, which reportedly in-
terfere with antibodies that target part of the E2-CD81 binding
site. In particular, these antibodies targeted broadly neutralizing
epitopes located in a highly conserved region of E2 corresponding
to amino acids 412 to 423 (65, 66). This finding was contrary to
previous reports thatmurinemonoclonal antibodies to the region
encompassing aa 434 to 446 neutralized E2-CD81 binding (9) and
autologous H77c HCVpp infectivity (27). In order to clarify this,
we studied the prevalences and neutralizing phenotypes of anti-
bodies that target these two regions from sera from two chroni-
cally infected individuals. Crucially, our data, derived by using
affinity-purified human Ig fractions, showed that human antibod-
ies that recognize both of these regions neutralized HCVpp and
HCVcc. We did not observe any interference between these two
groups of antibodies. The depletion of antibodies that target the
region encompassing aa 412 to 423 and aa 434 to 446 with satu-
FIG 7 Peptide I-Ig and peptide II-Ig display additive neutralization of HCVpp andHCVcc infection. Increasing concentrations of 1A76 peptide II-Ig (), 3A64
peptide II-Ig (Œ), or MAb 2/69a (o) were supplemented into neutralization reaction mixtures using fixed concentrations (approximate IC50s) of 1A76 peptide
I-Ig, 3A64 peptide I-Ig, orMAbAP33 and eitherHCVpp supplementedwithH77c E1E2 (A) or anHCVcc chimera possessing the structural proteins ofH77c (B).
A fixed concentration of HIV-1-specific antibody 2F5 (’) was used as a control antibody. The residual infectivity, expressed as a percentage of that observed in
the absence of antibody, is plotted against the concentration of the supplemented antibody. The neutralization obtained with peptide I-Ig or MAb AP33 in the
absence of the supplementary antibody is indicated by the dashed lines. Dose-dependent additive neutralizationwas consistently observed for all patient-isolated
antibody preparations and MAb combinations. The mean infectivities observed at the highest concentrations of each test antibody and the negative-control
antibody were compared by using a t test. P values are indicated as follows: ns, P 0.05; , P 0.05; , P 0.01; , P 0.001.
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rating amounts of peptide had a minimal effect on the overall
neutralizing titer (data not shown), confirming our previously
reported observation that antibody specificities to these epitopes
contribute only a small part of the total polyclonal neutralizing
response in chronically infected subjects (55).
Analysis of sera obtained from more than 500 individuals in-
fected with a broad range of HCV genotypes revealed that the
overall prevalence of peptide I-targeting antibodies was less than
3%, in accordance with our previously reported estimate (55). In
contrast, Zhang et al. reported previously that two of nine chron-
FIG 8 Epitope mapping by enrichment of random peptide phage display libraries reveals the presence of distinct yet overlapping epitopes within regions of E2
encompassing aa 412 to 423 and aa 434 to 446. Affinity-purified Ig from patients 3A64 (A) and 1A76 (B) andMAb 2/69a (C) were used to enrich phages from a
12-mer random peptide library. Following three to four rounds of biopanning, individual phage clones were isolated, amplified, and tested for reactivity to the
selecting antibody, and the amino acid sequence of the peptide insert was determined by DNA sequencing. The resulting sequences were aligned to the
corresponding region of theH77c E2 amino acid sequence. The phage clone identification is presented, and individual residues aligning to theH77c sequence are
shaded. Numbers in parentheses indicate the number of times each peptide sequence was recovered. The reactivity of each phage to the selecting antibody in a
phage capture enzyme immunoassay is shown alongside each peptide sequence and is shown as the relative optical density compared to that of capture by an
antibody preparation from an HCV-negative donor (NHS-Ig).,4-fold greater than the optical density obtained for the negative control NHS-IgG;
3-fold greater; , 1.5-fold greater; , 1.5-fold greater. In addition, the consensuses of the RNA sequences of the viruses infecting patient 3A64 were
deduced by reverse transcription-PCR (RT-PCR) and sequencing (A). This sequence is presented below the alignment for the peptides selected by antibodies
isolated from patient 3A64.
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ically infected patients harbored antibodies specific for a slightly
extended (aa 412 to 425) peptide I (66). It is possible that extend-
ing the peptide increased the detection of antibodieswith different
specificities; however, this is not supported by previously reported
mapping experiments, which suggested that the additional resi-
dues had no impact on antibody recognition (65, 66). Similar to
the findings reported previously by Zhang et al., we confirmed
that antibodies that target the region encompassing aa 412 to 423
coexisted with those that target the region encompassing aa 434
to 446.
Random peptide phage display epitope mapping experiments
showed that both regions contained overlapping, yet distinct,
epitopes. Phage binding enzyme immunoassays enabled the iden-
tification of specific binding mimotopes, thereby increasing our
confidence that the canonical sequences identified key residues
involved in binding. This is important, as the biopanning process
can also enrich for irrelevant peptides (40). Some of our selected
phage-displayed peptides did not demonstrate specific binding to
their selecting antibody despite possessing sequence motifs that
would implicate specific enrichment during selection. It is possi-
ble that the affinity of the interaction between these phage-
displayed peptides and the target antibody falls below the sensitiv-
ity of our assays. Further experiments are under way to investigate
this possibility.
Analysis of the peptide sequences of phages enriched using
peptide I-Ig from both patients 1A76 and 3A64 revealed a consis-
tent preservation of tryptophan, corresponding to W420, which
we had previously shown to be essential for recognition bymurine
MAbs AP33 and 3/11 (56) and human MAb e137 (47). This was
also implicated in the binding ofHCV immunoglobulin (HCVIG)
pools to an equivalent peptide antigen (66). While some critical
residues were common, phage mapping experiments showed that
the exact epitopes targeted by the patients’ antibodies differed.
Global conformation can also affect the exposure of epitopes
within this region (48). Both of these factors are likely to contrib-
ute to the differences in the neutralization breadths and potencies
of antibodies that target this conserved region of E2. In contrast,
the region encompassing aa 434 to 446 contains both variable and
conserved residues, both of which were targeted by peptide II-Ig
and MAb 2/69a. This variability impacts the neutralization
breadths and potencies observed for the various antibodies spe-
cific for the region encompassing aa 434 to 446. Finally, we have
recently shown that different E1E2s exhibit inherent differences in
the overall sensitivity to antibody neutralization, which is inde-
pendent of genotype. In particular, we have shown that H77c
E1E2 is one of the most easily neutralized (57).
It is possible that different epitope specificities might explain
the contrast in neutralizing antibody phenotypes identified here
compared to the interfering phenotype reported previously by
Zhang et al. However, peptide mapping of epitopes recognized by
peptide II-Ig fractions and MAb 2/69a revealed that they collec-
tively targeted epitopes spanning almost the entire region encom-
passing aa 434 to 446. Furthermore, in their mapping experi-
ments, Zhang et al. showed that themajority of the reactivity of the
interfering antibodies in HCVIG was targeted to residues 440 to
445, which is encompassed within the proposed 2/69a epitope.
Together, these findings would argue against there being both
neutralizing and interfering antibodies against this region.
Antibody-based immune selection is known to play a role in
the evolution of intrahost HCV populations (12, 17, 36). As the
region of E2 under investigation tolerates genetic diversity at spe-
cific amino acid positions, we examined whether the presence of
these antibodies resulted in the selection of novel variants in these
patients. PCR amplification of the full-length E1E2 coding region
was possible only for sera of patient 3A64. Interestingly, the E1E2
coding sequence of the virus present in this patient contained
several mutations compared to theH77c sequence, some of which
were predicted antibody contact residues. It was demonstrated
recently that amino acid substitutions at positions 443 and 444
may be involved in escape from antibody neutralization (17). The
phenotype of this variant virus is currently being assessed.
We have previously shown that residues within the region en-
compassing aa 412 to 423 are involved in CD81 binding (46).
Similarly, mutational analysis of a fragment of the region of aa 434
to 446, encompassing the sequence 436GWLAGLFY443, implicated
a role for this region in CD81 binding (15). Therefore, it is likely
that antibodies that target both of these regions neutralize HCV
entry by directly blocking the interaction between E2 and the cel-
lular receptor CD81. Importantly, the demonstration that some
peptide II-Ig was capable of cross-neutralization and could be
used in combination with antibodies that target the region en-
compassing aa 412 to 423 could inform the development of future
antibody therapies. In conclusion, this study has shown that hu-
man antibodies that target the region encompassing aa 434 to 446,
which were previously thought to reduce the neutralizing potency
of broadly neutralizing antibodies that target epitopes located
within the region encompassing aa 412 to 423, are not inhibitory
but are instead capable of neutralizing HCVpp and HCVcc entry.
It is difficult to explain this discrepancy, but our findings are con-
sistentwith previously reported data demonstrating the inhibition
of CD81 binding and with the limited HCVpp neutralization data
obtained for murine MAbs that target this region.
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